CANbridge Pharmaceuticals
CANbridge Pharmaceuticals is a Beijing-based, HKEX-listed biopharmaceutical company developing and commercializing rare disease therapeutics for the Greater China market, with three approved drugs (Hunterase, Livmarli, Gaurunning) and a pipeline spanning gene therapies and biologics targeting lysosomal storage disorders, cholestatic liver diseases, and neuromuscular conditions.
- Company typePublic
- Founded2012
- HeadquartersBeijing, China
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What CANbridge Pharmaceuticals does
CANbridge Pharmaceuticals is a global biopharmaceutical company headquartered in Beijing, China, and listed on the Hong Kong Stock Exchange (HKEX:1228), focused on developing and commercializing therapeutics for rare diseases and rare oncology conditions. Founded in 2012 by Dr. James Xue, a former Genzyme China general manager, the company operates three approved drugs: Hunterase (idursulfase beta) for MPS II, Livmarli (maralixibat) for ALGS and PFIC cholestatic pruritus, and Gaurunning (velaglucerase-beta) for Gaucher disease, with the latter representing the first domestically developed enzyme replacement therapy in China. The pipeline includes seven or more assets spanning monoclonal antibodies (CAN106 for PNH), additional enzyme replacement therapies, and gene therapies (CAN201, CAN202, CAN203, CAN204) targeting Fabry disease, Pompe disease, SMA, and Duchenne muscular dystrophy using proprietary AAV delivery platforms including sL65 capsid technology and StitchR RNA Assembly Technology licensed from LogicBio and Scriptr Global respectively.
The company's business model combines in-licensing of global rare disease assets for the Greater China market with proprietary R&D and gene therapy platform development. Revenue is generated through direct commercialization in mainland China via a sales-led motion, supplemented by regional distribution partners in Hong Kong and Taiwan, plus licensing and royalty income from outbound partnerships (e.g., Mirum Pharma, GC Pharma). CANbridge operates offices across Beijing, Shanghai, Hong Kong, Taipei, Burlington (Massachusetts), and a manufacturing facility in Suzhou, supported by approximately 101-250 employees of whom 42% hold Ph.D. or M.D. degrees. Strategic shareholders include WuXi AppTec (corporate investment plus board representation since June 2025) and Baheal Pharmaceutical Group (strategic partnership and investment since August 2025), while the company maintains research collaborations with UMass Chan Medical School and the University of Washington School of Medicine.
The competitive positioning leverages first-mover advantage in China's rare disease therapeutics market, exclusive Greater China distribution rights from multiple global partners, and priority review regulatory pathways granted by NMPA. The company has secured orphan drug designations and established an integrated manufacturing capability via the MAH system in China. Key revenue drivers include NRDL inclusion for three rare disease drugs in 2025 and Commercial Health Insurance Innovative Drug List placement for Gaurunning, though the company has historically operated at a loss with improving EBITDA trajectory and a recent net income inflection.
CANbridge Pharmaceuticals firmographics
Firmographics- Name
- CANbridge Pharmaceuticals
- Legal name
- CANbridge Life Sciences Ltd.
- Website
- https://canbridgepharma.com
- Company type
- Public
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- CANbridge Pharmaceuticals is a Beijing-based, HKEX-listed biopharmaceutical company developing and commercializing rare disease therapeutics for the Greater China market, with three approved drugs (Hunterase, Livmarli, Gaurunning) and a pipeline spanning gene therapies and biologics targeting lysosomal storage disorders, cholestatic liver diseases, and neuromuscular conditions.
- Ownership category
- akta.pro rank
CANbridge Pharmaceuticals industry classification
Industry- Product category
- Rare Disease Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)
Keywords
Where CANbridge Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Beijing
- HQ country
- China
- HQ region
- Asia
Offices6 records
Markets served
CANbridge Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others
Revenue model
- Pharmaceutical Product Sales: Revenue from commercialization of approved rare disease drugs including Hunterase, Livmarli, and Gaurunning in Greater China markets
- Licensing and Royalty Revenue: Income from licensing agreements with global partners for development and commercialization rights
- Strategic Partnerships: Collaborations with WuXi Biologics, Mirum Pharma, GC Pharma providing development milestones and commercialization support
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
CANbridge Pharmaceuticals product offering
Product offeringCore offering
CANbridge Pharmaceuticals develops, manufactures, and commercializes therapeutics for rare diseases and rare oncology, anchored by three approved drugs — Hunterase® (MPS II), Livmarli® (ALGS/PFIC), and Gaurunning® (Gaucher disease) — sold in Greater China through a direct sales force and regional distributors. Its pipeline extends these capabilities with a long-acting anti-C5 monoclonal antibody (CAN106) for complement-mediated diseases and a gene therapy portfolio (CAN201, CAN202, CAN204) built on AAV/sL65 delivery and StitchR RNA Assembly Technology, supplemented by in-licensed products and global licensing partnerships.
Product overview
CANbridge Pharmaceuticals is a global biopharmaceutical company with a foundation in China focused on rare diseases and rare oncology. The company operates a differentiated drug portfolio comprising 3 approved drugs (Gaurunning®, Livmarli®, and Hunterase®) and a pipeline of 7+ assets in various stages of development. The approved products include enzyme replacement therapies (ERTs) for lysosomal storage disorders like Gaucher disease and MPS II, and an IBAT inhibitor for rare cholestatic liver diseases. The pipeline includes biologics (monoclonal antibodies like CAN106), small molecules, and gene therapies targeting conditions such as complement-mediated disorders, metabolic diseases, and neuromuscular diseases. The company is also developing next-generation gene therapies for rare genetic diseases including Pompe disease, Fabry disease, and Duchenne muscular dystrophy through its Next-Generation Innovation and Process Development Facility.
Differentiator
Problem solved
Functional benefit
Products and services
- Hunterase® (Idursulfase beta / CAN101) Recombinant human iduronate-2-sulfatase enzyme replacement therapy (ERT) for long-term treatment of patients with mucopolysaccharidosis type II (MPS II / Hunter syndrome); marketed in mainland China, Hong Kong, and Taiwan.
- Livmarli® (Maralixibat / CAN108) Oral, minimally absorbed, reversible inhibitor of the ileal bile acid transporter (IBAT) for treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC); marketed in mainland China, Hong Kong, and Taiwan.
- Gaurunning® (Velaglucerase Beta for Injection / CAN103) Recombinant human glucocerebrosidase enzyme replacement therapy for long-term treatment of adult and pediatric patients (12 years and older) with Type 1 and Type 3 Gaucher disease; the first domestically developed ERT for Gaucher disease in China.
- CAN106 (Omoprubart) Novel, long-acting monoclonal antibody that specifically binds and neutralizes complement C5, being developed for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases including myasthenia gravis; partnered with Privus, which holds rights outside Greater China.
- CAN201 (Fabry disease gene therapy) AAV-based gene therapy using the sL65 capsid for treatment of Fabry disease (Anderson-Fabry disease), a lysosomal storage disease caused by deficiency of the alpha-galactosidase A enzyme; leverages gene delivery platform licensed from LogicBio Therapeutics.
- CAN202 (Pompe disease gene therapy) AAV-based gene therapy using the sL65 capsid for treatment of Pompe disease (Glycogen Storage Disease Type II), an autosomal recessive metabolic disease causing muscle and nerve cell damage due to glycogen accumulation in lysosomes.
- CAN204 (DMD/BMD gene therapy program) Dual AAV vector gene therapy using the StitchR RNA Assembly Technology for treatment of dystrophinopathies including Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and X-linked dilated cardiomyopathy; co-developed with University of Washington School of Medicine.
Quantifiable outcome
- CAN103 pivotal trial met primary endpoint with statistically significant mean percentage reduction in spleen volume at 9 months (P<0.0001 for 60 U/kg, P<0.001 for 30 U/kg)
- +2 more outcomes
Companies that use CANbridge Pharmaceuticals
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
CANbridge Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
CANbridge Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and minor.
- Baheal (百洋医药)coreStrategic partnership and investment from Baheal to strengthen commercialization of rare disease products. Baheal provides commercial capabilities and strategic investment.
- PrivusminorPartnership for CAN106 (omoprubart) complement C5 antibody with Privus holding rights outside Greater China while CANbridge has Greater China rights.
- University of Washington School of MedicineminorResearch agreement for Duchenne muscular dystrophy gene therapy development.
- Scriptr GlobalcoreLicensed StitchR RNA Assembly Technology globally for development of gene therapies targeting dystrophinopathies including DMD, BMD, and X-linked dilated cardiomyopathy. Published research in Science journal.
- LogicBio TherapeuticscoreLicensed gene delivery and editing technology platforms including sL65 capsid for development of gene therapies targeting Fabry disease and Pompe disease. Acquired global exclusive rights for the sL65 AAV capsid technology.
- Mirum PharmacoreExclusive licensing agreement to develop and commercialize maralixibat (Livmarli/CAN108) in Greater China for rare liver diseases including ALGS and PFIC. Mirum holds US/EU rights while CANbridge has Greater China rights.
- UMass Chan Medical SchoolcoreResearch collaboration for rare disease gene therapies. Partnership expanded with second agreement in September 2020. Includes development of SMA gene therapy (CAN203) and collaboration on AAV delivery platforms.
- GC PharmacoreLicensed Hunterase (idursulfase beta) for MPS II treatment in Greater China. GC Pharma originally developed Hunterase and maintains manufacturing capabilities while CANbridge commercializes in Greater China.
- WuXi Biologics (药明生物)coreStrategic partnership for rare disease therapeutics development. WuXi Biologics collaborated with CANbridge on CAN103 (velaglucerase-beta) development - the first enzyme replacement therapy developed in China for Gaucher disease. WuXi Biologics provides manufacturing capabilities and technology transfer for the MAH system.
- ApogenixminorLicensed CAN008 (asunercept) for treatment of glioblastoma multiforme in Greater China. CANbridge holds exclusive rights for any indication development in the region.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
CANbridge Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Zai Lab: China-founded, US/HK-listed biopharma licensing global innovative therapies for Greater China commercialization. Highly comparable bridge model with approved products across oncology and rare diseases, similar HKEX listing profile, and analogous reliance on in-licensed assets.
- Everest Medicines: Hong Kong-listed clinical-stage biopharma focused on licensing and developing innovative therapies for Asia-Pacific markets, including rare and infectious diseases. Directly comparable GTM (bridge model, HKEX listing) and overlapping rare disease focus.
- Mirum Pharmaceuticals: US rare disease biopharma developing Livmarli (maralixibat) for ALGS/PFIC and other cholestatic diseases. Direct counterparty and licensor to CANbridge; comparable business model centered on a single rare disease franchise with global rights.
- GC Pharma (Green Cross Corporation): Korean biopharma that developed Hunterase (idursulfase beta) for MPS II. Originator and licensor of one of CANbridge's flagship products; similar rare disease focus with established ERT portfolio across Asia.
Broad incumbents
- BioMarin Pharmaceutical: Global rare disease leader with multiple approved enzyme replacement and gene therapies (Vimizim, Naglazyme, Aldurazyme, Roctavian). Overlaps with CANbridge's Gaucher/MPS/gene therapy areas and represents the dominant global competitor in lysosomal storage disorders.
- Ultragenyx Pharmaceutical: US rare and ultra-rare disease biopharma with approved ERTs (Crysvita, Mepsevii, Dojolvi) and a gene therapy pipeline. Directly comparable in commercial-stage rare disease biologics and gene therapy modality.
- Sanofi Genzyme: Global rare disease franchise of Sanofi, the dominant player in lysosomal storage disorders (Cerezyme, Fabrazyme, Aldurazyme, Elaprase, Cerezyme). CANbridge's leadership is largely ex-Genzyme and the franchise's product overlap (Gaucher, MPS) makes it the benchmark competitor in China.
- Innovent Biologics: China-founded biopharma with HKEX listing and integrated R&D-manufacturing-commercial capabilities. Comparable scale, public-market profile, and Suzhou-based manufacturing footprint (CANbridge's Will Wang previously served at Innovent).
Regional players
- I-Mab Biopharma: China-focused clinical-stage biopharma with oncology and immunology focus; comparable HKEX/Nasdaq-listed structure, China innovation pipeline, and overlap in board-level rare disease regulatory talent (Rebecca Zhang, now CANbridge's Chief Regulatory Advisor, was previously Head of RA at I-Mab).
Emerging players
- Voyager Therapeutics: US clinical-stage gene therapy company developing AAV-based therapies for CNS diseases, co-founded by CANbridge SAB member Guangping Gao. Comparable gene therapy platform technology and shared scientific heritage in AAV delivery.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights6 records
Customer concentration
CANbridge Pharmaceuticals social profiles
Digital presenceCANbridge Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
CANbridge Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles19 records
CANbridge Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds7 records
Investors22 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CANbridge Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CANbridge Pharmaceuticals
What does CANbridge Pharmaceuticals do?
CANbridge Pharmaceuticals develops, manufactures, and commercializes therapeutics for rare diseases and rare oncology, anchored by three approved drugs — Hunterase® (MPS II), Livmarli® (ALGS/PFIC), and Gaurunning® (Gaucher disease) — sold in Greater China through a direct sales force and regional distributors. Its pipeline extends these capabilities with a long-acting anti-C5 monoclonal antibody (CAN106) for complement-mediated diseases and a gene therapy portfolio (CAN201, CAN202, CAN204) built on AAV/sL65 delivery and StitchR RNA Assembly Technology, supplemented by in-licensed products and global licensing partnerships.
Is CANbridge Pharmaceuticals a public or private company?
CANbridge Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was CANbridge Pharmaceuticals founded?
CANbridge Pharmaceuticals was founded in 2012. It employs 101 to 250 people.
Where is CANbridge Pharmaceuticals based?
CANbridge Pharmaceuticals is headquartered in Beijing, China, in the Asia region.
How does CANbridge Pharmaceuticals make money?
Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Royalty Revenue and strategic Partnerships.
Who are CANbridge Pharmaceuticals's main competitors?
Direct peers on record are Zai Lab, Everest Medicines, Mirum Pharmaceuticals and GC Pharma (Green Cross Corporation). Broad incumbents are BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, Sanofi Genzyme and Innovent Biologics. I-Mab Biopharma is listed as a regional player. Voyager Therapeutics is listed as an emerging player.
Does CANbridge Pharmaceuticals have an API?
No public API is recorded for CANbridge Pharmaceuticals.
What industry is CANbridge Pharmaceuticals in?
CANbridge Pharmaceuticals's product category is Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAO, Specialty Injectable & Infusion Therapies (Cross-therapeutic). Its NAICS code is 325412 and its SIC code is 2834.